Ulrika Andersson
About
In The Last Decade
Ulrika Andersson
52 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 113
- Cardiology and Cardiovascular Medicine 2.0k
- Internal Medicine 636
- Molecular Biology 366
- Epidemiology 324
- Physiology 288
Countries citing papers authored by Ulrika Andersson
This map shows the geographic impact of Ulrika Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrika Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrika Andersson more than expected).
Fields of papers citing papers by Ulrika Andersson
This network shows the impact of papers produced by Ulrika Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrika Andersson. The network helps show where Ulrika Andersson may publish in the future.
Co-authorship network of co-authors of Ulrika Andersson
This figure shows the co-authorship network connecting the top 25 collaborators of Ulrika Andersson. A scholar is included among the top collaborators of Ulrika Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrika Andersson. Ulrika Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 16 | |
| 3 | 15 | |
| 4 | 31 | |
| 5 | 11 | |
| 6 | 17 | |
| 7 | Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation : Insights from the ARISTOTLE trial | 7 |
| 8 | 6 | |
| 9 | The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment | 1 |
| 10 | Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation | 1 |
| 11 | 80 | |
| 12 | 173 | |
| 13 | 304 | |
| 14 | 37 | |
| 15 | 31 | |
| 16 | Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy | 2 |
| 17 | Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy | 3 |
| 18 | 129 | |
| 19 | 38 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.